Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2795-2803

  Deng, Biao ^a   Zhang, Xiao Fei ^a   Zhu, Xu Chao ^a   Huang, Hua ^a   Jia, Hu Liang ^a   Ye, Qing Hai ^a   Dong, Qiong Zhu ^a   Qin, Lun Xiu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bcl 2; Hepatocellular carcinoma; Osteopontin; Prognosis; Recurrence

Indexed keywords

OSTEOPONTIN; PROTEIN BCL 2;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOPONTIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84892384428     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2737     Document Type: Article

References (35)

1. Wai PY and Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27: 103-118, 2008.
2. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sørensen ES and Denhardt DT: Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85: 728-736, 2002.
3. Frenzel A, Grespi F, Chmelewskij W and Villunger A: Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14: 584-596, 2009.
4. Yoo SH, Yoon YG, Lee JS, et al: Etoposide induces a mixed type of programmed cell death and overcomes the resistance conferred by Bcl-2 in Hep3B hepatoma cells. Int J Oncol 41: 1443-1454, 2012.
5. Spampanato C, De Maria S, Sarnataro M, et al: Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and downregulation of BCL-2 gene expression. Int J Oncol 40: 935-941, 2012.
6. Callagy GM, Pharoah PD, Pinder SE, et al: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12: 2468-2475, 2006.
7. Dawson SJ, Makretsov N, Blows FM, et al: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 103: 668-675, 2010.
8. Hung JH, Teng YN, Wang LH, et al: Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS One 6: e28977, 2011.
9. Zhao J, Dong L, Lu B, et al: Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 135: 956-968, 2008.
10. Zhu XD, Zhang JB, Zhuang PY, et al: High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26: 2707-2716, 2008.
11. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711, 2008.
12. Huang H, Zhang XF, Zhou HJ, et al: Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci 101: 1314-1319, 2010.
13. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593, 2007.
14. Ding ZB, Shi YH, Zhou J, et al: Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res 68: 9167-9175, 2008.
15. Butler WT and Ritchie H: The nature and functional significance of dentin extracellular matrix proteins. Int J Dev Biol 39: 169-179, 1995.
16. Coppola D, Szabo M, Boulware D, et al: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190, 2004.
17. Rittling SR and Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881, 2004.
18. Singhal H, Bautista DS, Tonkin KS, et al: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997.
19. Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066, 2001.
20. Hotte SJ, Winquist EW, Stitt L, Wilson SM and Chambers AF: Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95: 506-512, 2002.
21. Pan HW, Ou YH, Peng SY, et al: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003.
22. Ye QH, Qin LX, Forgues M, et al: Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9: 416-423, 2003.
23. Sun J, Xu HM, Zhou HJ, et al: The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 1-7, 2010.
24. Zhang H, Ye QH, Ren N, et al: The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132: 709-717, 2006.
25. Yan W, Qian C, Zhao P, et al: Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 12: 765-775, 2010.
26. Xie H, Song J, Du R, et al: Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 39: 167-172, 2007.
27. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885, 2005.
28. Cory S, Huang DC and Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607, 2003.
29. Tanaka S, Louie D, Kant J and Reed JC: Application of a PCR-mismatch technique to the BCL-2 gene: detection of point mutations in BCL-2 genes of malignancies with A t(14,18). Leukemia 6 (Suppl 3): S15-S19, 1992.
30. Cheng EH, Kirsch DG, Clem RJ, et al: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966-1968, 1997.
31. Lin YP, Zhu BZ, Yang MC, et al: Bcl-2 overexpression inhibits tetrachlorohydroquinone-induced apoptosis in NIH3T3 cells: a possible mechanism for tumor promotion. Mol Carcinog 40: 24-33, 2004.
32. Bivona TG, Quatela SE, Bodemann BO, et al: PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell 21: 481-493, 2006.
33. Schwartz PS and Hockenbery DM: Targeted therapies for epithelial cancers: in vivo efficacy of the BCL-2/BCL-XL inhibitor 2-MeAA. Cancer Biol Ther 6: 465-466, 2007.
34. Silvestrini R, Veneroni S, Daidone MG, et al: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
35. Tsamandas AC, Thomopoulos K, Gogos C, et al: Expresssion of bcl-2 oprotein in cases of acute and chronic viral hepatitis type B and type C: a clinicopathologic study. Dig Dis Sci 47: 1618-1624, 2002.